Replimune Group, Inc. REPL announced positive top-line results from the primary analysis of the IGNYTE study on lead pipeline candidate RP1, in combination with Bristol Myers’ BMY blockbuster ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback